OBJECTIVE: The substantial material and legislative investments in establishing and maintaining cytological screening in the Czech Republic represent barriers to a direct transition to primary HPV screening. Therefore, the LIBUSE project was implemented to test the efficacy of phasing in HPV DNA testing as a co-test to cytology in routine screening of women >30 years of age. METHODS: Women aged 30 to 60 years who underwent regular annual Pap smears were co-tested for HPV DNA with selective 16/18 genotyping at 3-year intervals. All HPV 16/18-positive cases and/or cases with a severe abnormality in cytology were sent for colposcopy; HPV non-16/18-positive cases and LSILs were graded using p16/Ki67 dual-stain cytology, and positive cases were sent for colposcopy. RESULTS: Overall, 2409 patients were included. After the first combined screening (year 'zero') visit, 7.4% of women were HPV-positive and 2.0% were HPV16/18-positive; only 8 women had severe Pap smear abnormalities. Triage by dual staining was positive in 21.9% of cases (28/128). Biopsy confirmed 34 high-grade precancer lesions. At the second combined visit (year 'three'), the frequency of HPV infection (5.3% vs. 7.4%) frequency of HPV16/18 (1.1% vs. 2.0%), referrals for colposcopy (35 vs. 83), and biopsy verified high-grade lesions (5 vs. 34) were significantly lower (all P ≤ 0.001). CONCLUSION: The addition of HPV DNA testing with selective genotyping of HPV16/18 to existing cytology screening significantly increased the safety of the program. The gradual introduction of HPV testing was well received by healthcare professionals and patients, and can facilitate transformation of the cytology-based screening. ClinicalTrials.gov Identifier: NCT05578833.
- MeSH
- barvení a značení MeSH
- časná detekce nádoru MeSH
- DNA MeSH
- dospělí MeSH
- dysplazie děložního hrdla * diagnóza MeSH
- infekce papilomavirem * MeSH
- lidé MeSH
- lidský papilomavirus 16 genetika MeSH
- lidský papilomavirus 18 genetika MeSH
- nádory děložního čípku * MeSH
- Papanicolaouův test MeSH
- plošný screening MeSH
- třídění pacientů MeSH
- vaginální stěr MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
This is the first large-scale cross-country analysis of patients with chronic lymphocytic leukemia (CLL) aimed to evaluate the incidence, types, and key prognostic factors of secondary malignancies, and to assess the impact on overall survival based on retrospective claims data from three Central European countries. We analyzed 25,814 newly diagnosed CLL patients from Czechia, Hungary, and Poland; 10,312 (39.9%) patients were treated for CLL in study periods between 2004 and 2016. Out of the treated patients, 1986 (19.3%) received the FCR therapy in the first line and 779 (7.6%) received FCR in subsequent lines. We observed that 33.7% of treated patients developed secondary malignancies during the study. Based on country estimates, the probability to develop a secondary malignancy within 4 years since starting the first-line FCR therapy ranged between 28.0% and 36.8%. We found the age at diagnosis, male gender, any malignancy prior to the CLL diagnosis, and the CLL treatment to be the key risk factors for developing secondary malignancies. Specifically, the FCR therapy was a statistically significant (p < 0.001) prognostic factor for risk increase with the hazard ratio between 1.46 and 1.60. Across the three Central European countries, we observed consistent results indicating FCR increased the risk of secondary malignancies in CLL patients. We conclude that secondary malignancies are clearly an undervalued burden for CLL patients, caregivers, and the healthcare system. When evaluating new therapies in regulatory and reimbursement decision making, the factor of secondary malignancies deserves deeper considerations.
- MeSH
- chronická lymfatická leukemie * farmakoterapie epidemiologie MeSH
- cyklofosfamid terapeutické užití MeSH
- lidé MeSH
- přežití po terapii bez příznaků nemoci MeSH
- protokoly antitumorózní kombinované chemoterapie škodlivé účinky MeSH
- retrospektivní studie MeSH
- rituximab terapeutické užití MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa MeSH
Hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) is a rare and life-threatening condition characterized by recurrent localized edema. We conducted a systematic screening of SERPING1 defects in a cohort of 207 Czech patients from 85 families with C1-INH-HAE. Our workflow involved a combined strategy of sequencing extended to UTR and deep intronic regions, advanced in silico prediction tools, and mRNA-based functional assays. This approach allowed us to detect a causal variant in all families except one and to identify a total of 56 different variants, including 5 novel variants that are likely to be causal. We further investigated the functional impact of two splicing variants, namely c.550 + 3A > C and c.686-7C > G using minigene assays and RT-PCR mRNA analysis. Notably, our cohort showed a considerably higher proportion of detected splicing variants compared to other central European populations and the LOVD database. Moreover, our findings revealed a significant association between HAE type 1 missense variants and a delayed HAE onset when compared to null variants. We also observed a significant correlation between the presence of the SERPING1 variant c.-21 T > C in the trans position to causal variants and the frequency of attacks per year, disease onset, as well as Clinical severity score. Overall, our study provides new insights into the genetic landscape of C1-INH-HAE in the Czech population, including the identification of novel variants and a better understanding of genotype-phenotype correlations. Our findings also highlight the importance of comprehensive screening strategies and functional analyses in improving the C1-INH-HAE diagnosis and management.
- MeSH
- hereditární angioedémy * diagnóza epidemiologie genetika MeSH
- inhibiční protein komplementu C1 * genetika MeSH
- lidé MeSH
- messenger RNA MeSH
- sestřih RNA MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika MeSH
INTRODUCTION: Observational studies have shown low bleeding rates in patients with atrial fibrillation (AF) treated by left atrial appendage closure (LAAC); however, data from randomized studies are lacking. This study compared bleeding events among patients with AF treated by LAAC and nonvitamin K anticoagulants (NOAC). METHODS: The Prague-17 trial was a prospective, multicenter, randomized trial that compared LAAC to NOAC in high-risk AF patients. The primary endpoint was a composite of a cardioembolic event, cardiovascular death, and major and clinically relevant nonmajor bleeding (CRNMB) defined according to the International Society on Thrombosis and Hemostasis (ISTH). RESULTS: The trial enrolled 402 patients (201 per arm), and the median follow-up was 3.5 (IQR 2.6-4.2) years. Bleeding occurred in 24 patients (29 events) and 32 patients (40 events) in the LAAC and NOAC groups, respectively. Six of the LAAC bleeding events were procedure/device-related. In the primary intention-to-treat analysis, LAAC was associated with similar rates of ISTH major or CRNMB (sHR 0.75, 95% CI 0.44-1.27, p = 0.28), but with a reduction in nonprocedural major or CRNMB (sHR 0.55, 95% CI 0.31-0.97, p = 0.039). This reduction for nonprocedural bleeding with LAAC was mainly driven by a reduced rate of CRNMB (sHR for major bleeding 0.69, 95% CI 0.34-1.39, p = .30; sHR for CRNMB 0.43, 95% CI 0.18-1.03, p = 0.059). History of bleeding was a predictor of bleeding during follow-up. Gastrointestinal bleeding was the most common bleeding site in both groups. CONCLUSION: During the 4-year follow-up, LAAC was associated with less nonprocedural bleeding. The reduction is mainly driven by a decrease in CRNMB.
- MeSH
- antikoagulancia škodlivé účinky MeSH
- cévní mozková příhoda * diagnóza etiologie prevence a kontrola MeSH
- fibrilace síní * komplikace diagnóza farmakoterapie MeSH
- krvácení chemicky indukované MeSH
- lidé MeSH
- prospektivní studie MeSH
- síňové ouško * chirurgie MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
BACKGROUND: The PRAGUE-17 (Left Atrial Appendage Closure vs Novel Anticoagulation Agents in Atrial Fibrillation) trial demonstrated that left atrial appendage closure (LAAC) was noninferior to nonwarfarin direct oral anticoagulants (DOACs) for preventing major neurological, cardiovascular, or bleeding events in patients with atrial fibrillation (AF) who were at high risk. OBJECTIVES: This study sought to assess the prespecified long-term (4-year) outcomes in PRAGUE-17. METHODS: PRAGUE-17 was a randomized noninferiority trial comparing percutaneous LAAC (Watchman or Amulet) with DOACs (95% apixaban) in patients with nonvalvular AF and with a history of cardioembolism, clinically-relevant bleeding, or both CHA2DS2-VASc ≥3 and HASBLED ≥2. The primary endpoint was a composite of cardioembolic events (stroke, transient ischemic attack, or systemic embolism), cardiovascular death, clinically relevant bleeding, or procedure-/device-related complications (LAAC group only). The primary analysis was modified intention-to-treat. RESULTS: This study randomized 402 patients with AF (201 per group, age 73.3 ± 7.0 years, 65.7% male, CHA2DS2-VASc 4.7 ±1.5, HASBLED 3.1 ± 0.9). After 3.5 years median follow-up (1,354 patient-years), LAAC was noninferior to DOACs for the primary endpoint by modified intention-to-treat (subdistribution HR [sHR]: 0.81; 95% CI: 0.56-1.18; P = 0.27; P for noninferiority = 0.006). For the components of the composite endpoint, the corresponding sHRs were 0.68 (95% CI: 0.39-1.20; P = 0.19) for cardiovascular death, 1.14 (95% CI: 0.56-2.30; P = 0.72) for all-stroke/transient ischemic attack, 0.75 (95% CI: 0.44-1.27; P = 0.28) for clinically relevant bleeding, and 0.55 (95% CI: 0.31-0.97; P = 0.039) for nonprocedural clinically relevant bleeding. The primary endpoint outcomes were similar in the per-protocol (sHR: 0.80; 95% CI: 0.54-1.18; P = 0.25) and on-treatment (sHR: 0.82; 95% CI: 0.56-1.20; P = 0.30) analyses. CONCLUSIONS: In long-term follow-up of PRAGUE-17, LAAC remains noninferior to DOACs for preventing major cardiovascular, neurological, or bleeding events. Furthermore, nonprocedural bleeding was significantly reduced with LAAC. (PRAGUE-17 [Left Atrial Appendage Closure vs Novel Anticoagulation Agents in Atrial Fibrillation]; NCT02426944).
- MeSH
- cévní mozková příhoda epidemiologie prevence a kontrola MeSH
- fibrilace síní terapie MeSH
- inhibitory faktoru Xa terapeutické užití MeSH
- krvácení epidemiologie MeSH
- lidé MeSH
- následné studie MeSH
- prospektivní studie MeSH
- senioři MeSH
- síňové ouško chirurgie MeSH
- tranzitorní ischemická ataka epidemiologie prevence a kontrola MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- hodnocení ekvivalence MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
Substituční imunoglobulinová léčba představuje nejúčinnější léčebný přístup u pacientů s vrozenými poruchami tvorby protilátek. Ty představují nejpočetnější skupinu pacientů z vrozených poruch imunitního systému. Národní registr primárních imunodeficiencí České republiky slouží, mimo jiné, jako užitečný nástroj k celonárodnímu monitorování spotřeby imunoglobulinových preparátů u pacientů s tímto onemocněním. Z celkového počtu 1 029 pacientů vedených v registru bylo celkem 501 (48,7 %) léčeno imunoglobulinovou substituční léčbou. Většina z nich patřila do skupiny pacientů s poruchou tvorby protilátek (479; 95,6 %), ostatní byli s diagnózami ze skupiny dalších dobře definovaných imunodeficiencí (16; 3,2 %), kombinovaných imunodeficiencí (5; 1,0 %) a poruch komplementového systému (1; 0,2 %). Většina pacientů na této substituci byla léčena klasickými imunoglobuliny subkutánními (212 pacientů; 42,3 %), dále intravenózními (179 pacientů; 35,7 %) a hyaluronidázou facilitovaným subkutánním podáním imunoglobulinů (98 pacientů; 19,6 %). U 12 pacientů (2,4 %) bylo prováděno intramuskulární podávání. Průměrná dávka se pohybovala pod doporučenou hodnotou 0,40 g/kg/měsíc (u intravenózních 0,32 g/kg/měsíc, u subkutánních 0,27 g/kg/měsíc, u facilitovaných subkutánních 0,37 g/kg/měsíc). Nejnižší sérové koncentrace IgG před podáním další dávky imunoglobulinové substituční léčby se u všech způsobů podávání průměrně pohybovaly nad 6 g/l. Substituční imunoglobulinová léčba pacientů v České republice zatím po stránce kvalitativní nedosahuje úrovně vyspělých států. Pro zlepšení kvality péče o imunodeficitní pacienty je i nadále důležité získávání validních dat o spotřebě těchto preparátů, a tak díky Národnímu registru umožňovat nutnou argumentaci v jednání se zdravotními pojišťovnami.
Immunoglobulin replacement therapy is the most frequently used therapeutic approach in patients with congenital defects of antibody production, which represent the largest group of patients among primary immunodeficiency disorders. The National registry of primary immunodeficiency disorders serves as a useful tool for nationwide monitoring of immunoglobulin replacement therapy consumption in this patient. Out of the total number of 1029 patients with referred in registry, a total of 501 (48.7%) of them were treated with immunoglobulin replacement therapy. The majority of patients belonged to the group of patients with antibody deficiency disorders (479; 95.6%), other patients suffered from dia- gnoses of other well-defined immunodeficiencies (16; 3.2%), combined immunodeficiencies (5; 1.0%) and defects of the complement system (1; 0.2%). Most patients were treated with conventional subcutaneous (212 patients; 42.3%), intravenous (179 patients; 35.7%), and finally hyaluronidase-facilitated subcutaneous immunoglobulin administration (98 patients; 19.6%). In 12 patients (2.4%), intramuscular administration was reported. The average dose of was below the recommended 0.40 g/kg/month (intravenous: 0.32 g/kg/month, conventional subcutaneous 0.27 g/kg/month, facilitated subcutaneous: 0.37 g/kg/month). The averaged trough IgG levels were 6 g/l for all routes of administration. The immunoglobulin replacement therapy of patients with primary immunodeficiency in the Czech Republic did not reach the level of developed countries. To maintain the quality of care for immunological patients, despite the worldwide increasing consumption of these drugs due to the expansion of treatment indications and limited human resources for their production, it is important to obtain valid data on usage of these drugs in our country.
- MeSH
- imunoglobulin G aplikace a dávkování MeSH
- injekce intramuskulární statistika a číselné údaje MeSH
- injekce subkutánní statistika a číselné údaje MeSH
- intravenózní imunoglobuliny aplikace a dávkování MeSH
- intravenózní podání statistika a číselné údaje MeSH
- lidé MeSH
- primární imunodeficience epidemiologie farmakoterapie klasifikace MeSH
- registrace statistika a číselné údaje MeSH
- spotřeba léčiv statistika a číselné údaje MeSH
- způsoby aplikace léků MeSH
- Check Tag
- lidé MeSH
- Geografické názvy
- Česká republika MeSH
INTRODUCTION: The randomized PRAGUE-17 trial demonstrated noninferiority of left atrial appendage closure (LAAC) to non-vitamin K anticoagulants (NOACs) for the prevention of major cardiovascular or cerebrovascular events. However, the left atrial appendage is an important source of natriuretic peptides and plays a role in left atrial reservoir function. Changes of heart failure (HF) biomarkers after LAAC compared to NOAC has not been studied. The aim of the study was to compare the changes in concentrations of HF biomarkers between LAAC and NOAC patients. METHODS: Of 402 patients randomized in the PRAGUE-17 trial, biomarkers were analyzed in 144 patients (73 in the NOAC and 71 in the LAAC group). Both groups had similar baseline characteristics. Serum concentration of NT-proBNP, NT-proANP, Galectin-3, and GDF-15 were measured at baseline (before the procedure in the LAAC group), at the 6-month (and at 24-month for NT-proBNP) follow-up timepoint. RESULTS: There were no significant differences in baseline, 6 month, and delta (δ = baseline - 6 month) concentrations of NT-proANP between the groups (NOAC: baseline 2.6 [0.5; 4.9], 6-month 3.1 [1.8; 4.8], p = .068; LAAC: baseline 3.3 [1.1; 4.6], 6-month 2.6 [0.9; 5.3], p = .51; p value for δ in concentrations between groups = 0.42). Similarly, there were no significant differences in baseline, 6, 24 months, and delta concentrations of NT-proBNP between the groups (NOAC: baseline 461.0 [113.5; 1342.0], 6 month 440.0 [120.5; 1291.5], 24 month 798 [274; 2236], p = .39; LAAC: baseline 421.0 [100.0; 1320.0], 6 month 601.0 [145.0; 1230.0], 24 month 855 [410; 1367], p = .28; p value for δ in concentrations between groups = 0.73 at 6 months, and 0.58 at 24 months). Finally, no significant differences were present in baseline, 6 month, and δ concentrations of Galectin-3 and GDF-15 between the two groups. CONCLUSION: LAAC did not significantly influence the levels of HF biomarkers 6 months after the procedure.
- MeSH
- antikoagulancia terapeutické užití MeSH
- aplikace orální MeSH
- biologické markery MeSH
- cévní mozková příhoda * MeSH
- fibrilace síní * diagnóza farmakoterapie chirurgie MeSH
- lidé MeSH
- síňové ouško * diagnostické zobrazování chirurgie MeSH
- srdeční selhání * diagnóza farmakoterapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH